Biomarkers for the early diagnosis of glucocorticoid-induced glaucoma and their applications

By detecting SLPI and APOD in the aqueous humor, high-throughput transcriptome sequencing was used to screen differentially expressed genes and construct a joint diagnostic model, solving the problem of early diagnosis of glucocorticoid-induced glaucoma and achieving early warning and highly accurate diagnosis.

CN123108137APending Publication Date: 2026-11-17ZHONGNAN HOSPITAL OF WUHAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611239158.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-08-16
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Current technology makes it difficult to diagnose glucocorticoid-induced glaucoma in its early stages, resulting in patients seeking medical attention when the disease has progressed to the middle or late stages, missing the optimal intervention time. Furthermore, traditional diagnosis relies on lagging indicators and subjective responses.

Method used

By detecting the expression levels of SLPI and APOD in the aqueous humor, high-throughput transcriptome sequencing is used to screen differentially expressed genes, and a joint diagnostic model is constructed to achieve objective and quantitative assessment of disease status.

Benefits of technology

It provides early warning before the onset of clinical functional impairment, significantly improves diagnostic accuracy, provides stable and reliable data results, and the combined use of SLPI and APOD has a significant synergistic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123108137A_ABST
    Figure CN123108137A_ABST
Patent Text Reader

Abstract

This invention provides biomarkers for the early diagnosis of glucocorticoid-induced glaucoma and their applications, relating to the field of biomedical detection technology. The invention includes the following steps: S1, obtaining a biological sample from the subject; S2, detecting the expression levels of SLPI and / or APOD in the biological sample; S3, comparing the detection results with preset reference values. This biomarker for the early diagnosis of glucocorticoid-induced glaucoma and its application, by detecting SLPI and APOD in the early pathological stage of GIG, can provide early warning before the onset of clinical functional impairment. This is significantly superior to traditional diagnostic methods that rely on late-lag indicators such as intraocular pressure and visual field. Furthermore, unlike visual field examinations that heavily rely on patient cooperation and subjective responses, this invention achieves an objective and quantitative assessment of the disease state by detecting protein or mRNA levels in the aqueous humor, and the data results are more stable and reliable.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biomedical detection technology, specifically to biomarkers for the early diagnosis of glucocorticoid-induced glaucoma and their applications. Background Technology

[0002] Glucocorticoids are currently widely used first-line immunosuppressants in clinical practice, but long-term use may cause glucocorticoid-induced glaucoma (GIG) in people who are sensitive to hormones. This disease has an insidious onset and is characterized by persistent intraocular pressure elevation and progressive optic nerve damage, and has now become a serious public health problem.

[0003] Currently, the clinical diagnosis of glucocorticoid glaucoma (GIG) heavily relies on traditional indicators such as history of glucocorticoid use, intraocular pressure measurement, and visual field examination. However, these indicators all reflect late-stage functional impairment, resulting in most patients having already progressed to the middle or late stages of the disease when they seek medical attention, thus missing the best intervention opportunity.

[0004] Although the development of high-throughput transcriptome sequencing (RNA-seq) technology has enabled researchers to comprehensively and dynamically analyze changes in gene expression profiles in the trabecular meshwork under the influence of glucocorticoids, providing a rich data foundation for discovering potential molecular markers related to GIG, diagnosis based solely on changes in a single molecule from massive amounts of data often fails to meet the high-precision requirements of early clinical diagnosis due to low specificity. Summary of the Invention

[0005] This invention aims to address the shortcomings of the prior art by providing biomarkers for the early diagnosis of glucocorticoid glaucoma and their applications. To solve the aforementioned problems, by detecting SLPI and APOD in the early pathological stage of GIG, early warning can be achieved before the onset of clinical functional impairment, which is significantly better than the traditional diagnostic model that relies on late lagging indicators such as intraocular pressure and visual field. Moreover, unlike visual field examination, which heavily relies on patient cooperation and subjective response, this invention achieves an objective and quantitative assessment of the disease state by detecting the protein or mRNA levels in the aqueous humor, and the data results are more stable and reliable.

[0006] To achieve the above objectives, the present invention provides the following technical solution: biomarkers for the early diagnosis of glucocorticoid-induced glaucoma and their application, comprising the following steps: S1. Obtain biological samples from the subject to be tested; S2. Detect the expression levels of SLPI and / or APOD in the biological sample; S3. Compare the test results with the preset reference values.

[0007] Furthermore, step S1 is detailed as follows: S11. Human trabecular meshwork cells (HTMC) were selected as an in vitro model, and a glucocorticoid-induced model group was constructed. Untreated cells were set up as a control group. S12. Collect cell samples from the model group and the control group respectively, and extract total RNA; S13. High-throughput transcriptome sequencing was used to detect molecular expression levels, and the raw data were quality controlled and compared to obtain the expression matrix. S14. Statistical analysis of gene expression levels between the model group and the control group based on the expression matrix, and screening of differentially expressed genes; S15. Further validate the selected candidate molecules with significant differential expression; S16. Screen the results and identify SLPI and APOD as candidate biomarkers.

[0008] Furthermore, step S2 is detailed as follows: S21. Collect aqueous humor samples from clinically diagnosed glucocorticoid glaucoma (GIG) patients (n=16) and age-matched control group cataract surgery patients (n=16). S22. Detect protein expression, obtain detection results, and plot a standard curve to detect the protein concentrations of SLPI and / or APOD in the aqueous humor. S23. Statistical analysis was performed on the expression levels of SLPI and APOD between the GIG patient group and the control group to compare the differences between the two groups.

[0009] Furthermore, step S3 is as follows: S31. Based on the expression data obtained in S2, evaluate the diagnostic efficacy of SLPI and APOD in distinguishing between patients with glucocorticoid-induced glaucoma (GIG) and the control group. S32. Analyze SLPI and APOD separately and calculate their ROC curves and AUC values; S33. Using multivariate analysis, a combined diagnostic model of SLPI and APOD was constructed, and the combined AUC value was calculated to determine that the combined detection of SLPI and APOD can significantly improve the diagnostic accuracy of glucocorticoid-induced glaucoma.

[0010] (1) By detecting SLPI and APOD in the early pathological stage of GIG, early warning can be achieved before the clinical functional damage occurs, which is significantly better than the traditional diagnostic mode that relies on late lagging indicators such as intraocular pressure and visual field. Unlike visual field examination, which relies heavily on patient cooperation and subjective reaction, this invention achieves objective and quantitative assessment of the disease state by detecting the protein or mRNA level in aqueous humor, and the data results are more stable and reliable.

[0011] (2) The biomarkers provided by this invention have extremely high diagnostic accuracy, and the combined use of SLPI and APOD has been shown to have a significant synergistic effect. Attached Figure Description

[0012] Figure 1 This is a heatmap of differentially expressed genes in human trabecular meshwork cells (HTM cells) treated with dexamethasone (DEX) according to the present invention.

[0013] Figure 2 The image shows the results of dexamethasone (DEX)-treated human trabecular meshwork cells (HTM cells) and SLPI and APODqRT-PCR of the present invention.

[0014] Figure 3 This is a comparison chart of the ELISA results of SLPI and APOD protein concentrations in the aqueous humor of the GIG patient group and the control group (cataract patients) according to the present invention.

[0015] Figure 4 This is a comparison graph of receiver operating characteristic (ROC) curves and area under the curve (AUC) of the efficacy of SLPI (alone), APOD (alone), and SLPI and APOD combined for the diagnosis of GIG.

[0016] Figure 5 This is a schematic diagram of the process of the present invention.

[0017] Figure 6 This is a schematic diagram illustrating the specific steps of step S1 of the present invention.

[0018] Figure 7 This is a schematic diagram illustrating the specific steps of step S2 of the present invention.

[0019] Figure 8 This is a schematic diagram illustrating the specific steps of step S3 of the present invention. Detailed Implementation

[0020] The technical solutions of the embodiments of this application will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of this application, and not all embodiments. Based on the embodiments of this application, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of this application. In addition, unless otherwise specified, the raw materials, equipment, and methods used in this invention are all commonly used raw materials, equipment, or methods in the art.

[0021] The following disclosure provides many different embodiments or examples for implementing different structures of this application. To simplify the disclosure, specific examples of components and arrangements are described below. Of course, these are merely examples and are not intended to limit the scope of this application. Furthermore, reference numerals and / or letters may be repeated in different examples; such repetition is for simplification and clarity and does not in itself indicate a relationship between the various embodiments and / or arrangements discussed. In addition, various specific examples of processes and materials are provided in this application, but those skilled in the art will recognize the application of other processes and / or the use of other materials.

[0022] This application provides biomarkers for the early diagnosis of glucocorticoid-induced glaucoma and their applications. These biomarkers and their applications can provide early warning by detecting SLPI and APOD in the early pathological stages of GIG, enabling early detection before clinical functional impairment occurs. This is significantly superior to traditional diagnostic methods that rely on late-lag indicators such as intraocular pressure and visual field. Furthermore, unlike visual field examinations that heavily rely on patient cooperation and subjective responses, this invention achieves objective and quantitative assessment of the disease state by detecting protein or mRNA levels in the aqueous humor, resulting in more stable and reliable data. The following provides a detailed description of these biomarkers for the early diagnosis of glucocorticoid-induced glaucoma and their applications. It should be noted that the order of description in the following embodiments is not intended to limit the preferred order of the embodiments.

[0023] Furthermore, the English abbreviations used in this invention are explained as follows: GIG: Glucocorticoid-induced glaucoma; ROC: Receiver Operating Characteristic (ROC); AUC: Area under the ROC curve; SLPI: Secretory leukocyte protease inhibitor; APOD: Apolipoprotein D; Dex: Dexamethasone; HTMC: Human trabecular meshwork cells; qT-PCR: Real-time quantitative polymerase chain reaction; ELISA: Enzyme-linked immunosorbent assay (ELISA). In this invention, the term "diagnosis" refers to determining whether a subject currently has a specific disease or ailment, especially in the early stages of the disease; or to distinguish a subject with a specific disease or ailment from a normal subject or a subject with other interfering diseases (such as cataract patients), i.e., to assist in diagnosis.

[0024] In this invention, the terms "biomarker for diagnosis" or "diagnosis marker" refer to substances capable of distinguishing patients with glucocorticoid-induced glaucoma (GIG) from non-GIG control groups for diagnostic purposes. These biomarkers include, but are not limited to: proteins exhibiting differential expression levels in samples derived from GIG patients (preferably aqueous humor) compared to control samples; polypeptides derived from the aforementioned proteins; nucleic acids (such as mRNA) encoding the aforementioned proteins; or fragments thereof. The sequences of these biomarkers can be retrieved from the UniProt database or the NCBI database.

[0025] The biomarkers of this invention can be used alone or in combination of two biomarkers, and can be combined with other known diagnostic biomarkers or methods according to specific application needs to obtain a diagnostic solution that meets the expected diagnostic sensitivity and specificity. In this invention, the detection includes quantitative and / or qualitative analysis of the biomarkers, and the detection method can be either presence detection or expression level detection. Those skilled in the art can select an appropriate detection method to implement this invention according to specific application needs.

[0026] In this invention, the detection reagent is a reagent capable of quantitative and / or qualitative analysis of the biomarkers described herein based on protein and / or nucleic acid levels. In some embodiments, the detection reagent includes an immunological detection reagent for detecting the protein expression level of the biomarker, and / or a nucleic acid detection reagent for detecting the nucleic acid expression level encoding the biomarker.

[0027] As a qualitative or quantitative detection method based on protein levels, immunological detection methods can be used to detect the protein expression level of biomarkers. These immunological detection methods include, but are not limited to, ELISA, Western blot analysis, or other detection methods based on antigen-antibody specific binding.

[0028] In this invention, the term "kit" refers to a combination of one or more detection reagents for detecting the biomarkers described in this invention. The kit may be provided individually or in a single container. In some embodiments, the kit may also include instructional information for performing the detection method, guiding the user in analyzing and interpreting the test results. This invention also relates to the use of the kit in methods for diagnosing or assisting in the diagnosis of glucocorticoid-induced glaucoma.

[0029] In this invention, to screen and identify biomarkers for the early diagnosis of glucocorticoid-induced glaucoma (GIG), candidate biomarkers are obtained by statistically screening the differences in molecular expression between disease states and control states based on disease-related biological models or clinical samples. These biomarkers are then further validated and evaluated to confirm their application value in the diagnosis of GIG. The above process is only used to illustrate the biomarker screening approach in this invention and does not constitute a limitation on specific screening methods or steps.

[0030] The present application will now be described in detail with reference to the accompanying drawings and specific embodiments.

[0031] Please see Figure 1-8 The biomarkers for early diagnosis of glucocorticoid-induced glaucoma provided in this embodiment and their applications include the following steps: S1. Obtain biological samples from the subject to be tested; S2. Detect the expression levels of SLPI and / or APOD in the biological sample; S3. Compare the test results with the preset reference values.

[0032] Among them, because the molecular-level changes of key upregulated molecules (SLPI and APOD) in the early pathological process of GIG (trabecular meshwork ECM remodeling) occur much earlier than the increase in intraocular pressure or morphological changes in the optic nerve, the detection of this biomarker can provide early warning before the onset of clinical functional damage, which is significantly better than the traditional diagnostic model that relies on late lagging indicators such as intraocular pressure and visual field.

[0033] Secondly, unlike visual field examinations that heavily rely on patient cooperation and subjective responses, this invention achieves an objective and quantitative assessment of disease status by detecting protein or mRNA levels in the aqueous humor, resulting in more stable and reliable data.

[0034] Furthermore, the biomarkers provided by this invention all have extremely high diagnostic accuracy, and can demonstrate that the combined use of SLPI and APOD has a significant synergistic effect. The combined diagnostic AUC value can reach 0.988, with a sensitivity of 100% and a specificity of 93.7%, showing a synergistic diagnostic advantage and extremely high discriminative efficacy far exceeding that of individual biomarkers.

[0035] Finally, the detection methods provided by this invention are all clinically mature technologies, and aqueous humor samples can be obtained in routine ophthalmic surgery or anterior chamber puncture, making them easy to standardize in hospital laboratories and highly operable, thus providing a reliable approach for the early diagnosis of GIG.

[0036] Step S1 is as follows: S11. Human trabecular meshwork cells (HTMC) were selected as an in vitro model, and a glucocorticoid-induced model group was constructed. Untreated cells were set up as a control group. S12. Collect cell samples from the model group and the control group respectively, and extract total RNA; S13. High-throughput transcriptome sequencing was used to detect molecular expression levels, and the raw data were quality controlled and compared to obtain the expression matrix. S14. Statistical analysis of gene expression levels between the model group and the control group based on the expression matrix, and screening of differentially expressed genes; S15. Further validate the selected candidate molecules with significant differential expression; S16. Screen the results and identify SLPI and APOD as candidate biomarkers.

[0037] Furthermore, the specific method for screening biomarkers for glucocorticoid-induced glaucoma is as follows: (1) Model establishment: Human trabecular meshwork cells (HTMCs) were selected as the in vitro model. HTMCs were treated with dexamethasone (Dex) to construct a glucocorticoid-induced model group, while untreated cells were set up as the control group.

[0038] (2) Sample processing and RNA extraction: Cell samples from the model group and the control group were collected respectively, and total RNA was extracted.

[0039] (3) Transcriptome sequencing analysis: Gene expression in the two groups of samples was detected using high-throughput transcriptome sequencing technology. The raw data were quality controlled and compared to obtain the expression matrix.

[0040] (4) Differential expression analysis: Based on the above expression matrix, the gene expression levels between the model group and the control group were statistically analyzed, and differentially expressed genes were screened according to the preset significance level and expression change threshold.

[0041] (5) Validation of candidate molecules: Candidate molecules with significant differential expression were selected for further validation. The expression levels of these molecules in the model group and control group were detected by qRT-PCR and / or ELISA to confirm that their expression change trend was consistent with the transcriptome sequencing results and to verify their correlation with glucocorticoid-induced state.

[0042] (6) Screening results: The results showed that SLPI and APOD were significantly upregulated in Dex-treated HTMC cells compared with the control group. Therefore, SLPI and APOD were identified as candidate biomarkers.

[0043] like Figure 1The image shows a heatmap of differentially expressed genes identified by high-throughput transcriptome sequencing analysis. Compared with the control group, the mRNA expression of SLPI was upregulated by 6.29-fold (p<0.0001) and the mRNA expression of APOD was upregulated by 4.2-fold (p<0.0001) in the DEX-treated group. This suggests that both genes are associated with GIG pathology. These results can be further validated by qRT-PCR, such as... Figure 2 .

[0044] Based on the above results, the expression levels of SLPI and APOD were further validated in clinical samples to evaluate their potential application value in the diagnosis of glucocorticoid-induced glaucoma.

[0045] Step S2 is as follows: S21. Collect aqueous humor samples from clinically diagnosed glucocorticoid glaucoma (GIG) patients (n=16) and age-matched control group cataract surgery patients (n=16). S22. Detect protein expression, obtain detection results, and plot a standard curve to detect the protein concentrations of SLPI and / or APOD in the aqueous humor. S23. Statistical analysis was performed on the expression levels of SLPI and APOD between the GIG patient group and the control group to compare the differences between the two groups.

[0046] Furthermore, the specific method for detecting the expression of SLPI and APOD in the aqueous humor of GIG patients is as follows: 1. Sample Source: Aqueous humor samples were collected from clinically diagnosed glucocorticoid-induced glaucoma (GIG) patients (n=16) and age-matched control group cataract surgery patients (n=16). Samples were immediately stored at low temperature after collection and centrifuged before testing to remove cells and impurities. The supernatant was used for subsequent testing.

[0047] 2. Specific steps for detecting protein expression: (1) Prepare all reagents, working standards and samples; equilibrate the kit to room temperature. Remove the microplate strips from the plate frame.

[0048] (2) Add 100 μL of standard / sample diluent (R1) to the blank well.

[0049] (3) Add 100 μL of different concentrations of standard or sample to the other wells, seal the wells with the provided sealing film, and incubate at 37°C for 2 hours.

[0050] (4) Prepare the working solution of biotinylated antibody (100x) 15 minutes before use.

[0051] (5) Discard the liquid in the well, add 350 μL of 1× washing buffer to each well, let stand for 40 seconds and then discard the liquid. This step is repeated 3 times.

[0052] (6) Add biotinylated antibody working solution (100 μL / well) to each well, cover with a new sealing film, and incubate at 37°C for 1 hour.

[0053] (7) Prepare the working solution of streptavidin-HRP (100X) 15 minutes before use.

[0054] (8) Discard the liquid in the hole and repeat the washing step in step 5.

[0055] (9) Add streptavidin-HRP working solution (100 μL / well) to each well, cover with a new sealing film, and incubate at 37°C for 1 hour.

[0056] (10) Preheating enzyme-linked immunosorbent assay (ELISA) reader.

[0057] (11) Discard the liquid in the hole and repeat the washing step in step 5.

[0058] (12) Add TMB substrate (100 μL / well) to the well and incubate at 37°C in the dark for 15-20 minutes.

[0059] (13) Add stop solution (50 μL / well) and immediately place the well in the microplate reader. Measure the OD value of each well at 450 nm within 5 min. If a correction wavelength can be selected, set it to 570 nm or 630 nm. Subtract the 570 nm or 630 nm reading from the 450 nm reading. This method can correct and remove the OD value of non-chromogenic substances, thus obtaining more accurate detection results. If a correction wavelength cannot be selected, the obtained reading will be too high, resulting in decreased accuracy.

[0060] (14) Plot a standard curve and detect the protein concentrations of SLPI and / or APOD in the aqueous humor.

[0061] 3. Statistical Analysis and Results: Statistical analysis was performed on the expression levels of SLPI and APOD between the GIG patient group and the control group to compare the differences between the two groups. Results are as follows: Figure 3 As shown, the average concentration of SLPI in the aqueous humor of GIG patients was 24.66±2.78 ng / mL, which was significantly higher than that of the control group (15.59±3.48 ng / mL) (p<0.0001); the average concentration of APOD was 1743.07±194.39 ng / mL, which was significantly higher than that of the control group (972.76±206.73 ng / mL) (p<0.0001).

[0062] The above results indicate that SLPI and APOD are significantly upregulated in the aqueous humor of GIG patients, and have potential diagnostic value in distinguishing between disease states and control states.

[0063] Step S3 is as follows: S31. Based on the expression data obtained in S2, evaluate the diagnostic efficacy of SLPI and APOD in distinguishing between patients with glucocorticoid-induced glaucoma (GIG) and the control group. S32. Analyze SLPI and APOD separately and calculate their ROC curves and AUC values; S33. Using multivariate analysis, a combined diagnostic model of SLPI and APOD was constructed, and the combined AUC value was calculated to determine that the combined detection of SLPI and APOD can significantly improve the diagnostic accuracy of glucocorticoid-induced glaucoma.

[0064] Furthermore, the specific methods for evaluating the diagnostic efficacy of SLPI and APOD are as follows: 1. Analysis Methods: Based on the expression data obtained in Example 2, the diagnostic efficacy of SLPI and APOD in distinguishing between patients with glucocorticoid-induced glaucoma (GIG) and controls was evaluated. Receiver operating characteristic (ROC) curve analysis was used to calculate the area under the curve (AUC) to assess their discriminative ability.

[0065] 2. Single-index evaluation: SLPI and APOD were analyzed separately, and their ROC curves and AUC values ​​were calculated. The results showed that both SLPI (AUC=0.977) and APOD (AUC=0.941) had good discriminative ability.

[0066] 3. Joint Indicator Evaluation: A joint diagnostic model for SLPI and APOD was constructed using multivariate analysis—logistic regression. ROC curve analysis was performed on the joint model to calculate the joint AUC value.

[0067] The results are as follows Figure 4 The results showed that SLPI alone had an AUC of 0.977 and a cutoff concentration of 20.46 ng / ml for diagnosing GIG, while APOD alone had an AUC of 0.941 and a cutoff concentration of 1377.15 ng / ml. However, when SLPI and APOD were combined and diagnosed using binary logistic regression, the combined AUC reached 0.988, with a sensitivity of 100% and a specificity of 93.7%.

[0068] The above results indicate that the combined detection of SLPI and APOD can significantly improve the diagnostic accuracy of glucocorticoid-induced glaucoma, with high sensitivity and specificity.

[0069] In the above embodiments, the descriptions of each embodiment have different focuses. For parts not described in detail in a certain embodiment, please refer to the relevant descriptions in other embodiments.

[0070] The above provides a detailed description of the biomarkers for early diagnosis of glucocorticoid-induced glaucoma and their applications provided in the embodiments of this application. Specific examples have been used to illustrate the principles and implementation methods of this application. The descriptions of the above embodiments are only for the purpose of helping to understand the technical solutions and core ideas of this application. Those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some of the technical features. These modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of this application.

Claims

1. A biomarker for the early diagnosis of glucocorticoid-induced glaucoma and its application, characterized in that, Includes the following steps: S1. Obtain biological samples from the subject to be tested; S2. Detect the expression levels of SLPI and / or APOD in the biological sample; S3. Compare the test results with the preset reference values.

2. The biomarker for early diagnosis of glucocorticoid-induced glaucoma according to claim 1 and its application, characterized in that, Step S1 is as follows: S11. Human trabecular meshwork cells (HTMC) were selected as an in vitro model, and a glucocorticoid-induced model group was constructed. Untreated cells were set up as a control group. S12. Collect cell samples from the model group and the control group respectively, and extract total RNA; S13. High-throughput transcriptome sequencing was used to detect molecular expression levels, and the raw data were quality controlled and compared to obtain the expression matrix. S14. Statistical analysis of gene expression levels between the model group and the control group based on the expression matrix, and screening of differentially expressed genes; S15. Further validate the selected candidate molecules with significant differential expression; S16. Screen the results and identify SLPI and APOD as candidate biomarkers.

3. The biomarker for early diagnosis of glucocorticoid-induced glaucoma according to claim 1 and its application, characterized in that, Step S2 is as follows: S21. Collect aqueous humor samples from clinically diagnosed glucocorticoid glaucoma (GIG) patients (n=16) and age-matched control group cataract surgery patients (n=16). S22. Detect protein expression, obtain detection results, and plot a standard curve to detect the protein concentrations of SLPI and / or APOD in the aqueous humor. S23. Statistical analysis was performed on the expression levels of SLPI and APOD between the GIG patient group and the control group to compare the differences between the two groups.

4. The biomarker for early diagnosis of glucocorticoid-induced glaucoma according to claim 1 and its application, characterized in that, Step S3 is as follows: S31. Based on the expression data obtained in S2, evaluate the diagnostic efficacy of SLPI and APOD in distinguishing between patients with glucocorticoid-induced glaucoma (GIG) and the control group. S32. Analyze SLPI and APOD separately and calculate their ROC curves and AUC values; S33. Using multivariate analysis, a combined diagnostic model of SLPI and APOD was constructed, and the combined AUC value was calculated to determine that the combined detection of SLPI and APOD can significantly improve the diagnostic accuracy of glucocorticoid-induced glaucoma.